X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

    Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

    Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

    Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

    Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

    Sygnature expands capabilities with acquisition of Alderley Oncology

    SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    Regeneron, Intellia to develop CRISPR/Cas9-based treatments

    BioMed X Launches New T Cell Immunology Discovery Platform

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

    Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

    Biotech Companies In China Look To Have A Global Footprint

    Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

    Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

    Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

    Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

    Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

    Sygnature expands capabilities with acquisition of Alderley Oncology

    SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    Regeneron, Intellia to develop CRISPR/Cas9-based treatments

    BioMed X Launches New T Cell Immunology Discovery Platform

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

    Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

    Biotech Companies In China Look To Have A Global Footprint

    Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

Content Team by Content Team
21st February 2023
in FDA Approvals, News
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

GC Biopharma, a leading provider of biopharmaceutical products in South Korea, announced that the World Health Organization (WHO) has granted prequalification for the company’s varicella vaccine, Barycela.

WHO prequalification decision has made Barycela now eligible for procurement by the United Nations agencies, including the Pan American Health Organization (PAHO), to be used in national immunization programmes. Barycela is now one of the three PQ vaccines that GC Biopharma has obtained so far along with H1N1 pandemic and seasonal influenza vaccines.

Barycela is a live attenuated varicella virus vaccine, containing MAV/06 strain, a virus exclusively attenuated by GC Biopharma. While containing higher amount of virus, this new vaccine, compared to its previous product, shows higher level of product stability. Barycela has also proved non-inferior in immunogenicity with an equivalent level of safety to “Varivax”, an existing prequalified vaccine in the market.

In addition, Barycela is being produced in a state-of-the-art aseptic condition from cell culture and virus infection to purification to make it the world’s single only varicella vaccine produced without antibiotics.

With the WHO’s prequalification decision, MAV/06 strain has moved a step closer to being registered in the WHO Technical Report Series (TRS) along with the previously listed OKA strain.

GC Biopharma’s next plan is to target global markets with Barycela. The strategy is to utilize the global supply network for Suduvax, its existing varicella vaccine.

“We hope Barycela will continue our contribution to reducing the world’s social and economic cost incurred by varicella outbreaks.” said EC Huh, Ph.D., president of GC Biopharma.

Developed in 1993, GC Biopharma’s Suduvax is Korea’s first and the world’s second varicella vaccine. Over 28million doses of the vaccine have been sold worldwide over the past 3 decades through PAHO and others, proving its high level of safety.

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century.

 

 

Previous Post

Clover Launches COVID-19 Booster Vaccine in the People's Republic of China

Next Post

DoKaSch Temperature Solutions and ANA sign master rental agreement

Related Posts

United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
News

DoKaSch Temperature Solutions and ANA sign master rental agreement

21st February 2023
Sygnature expands capabilities with acquisition of Alderley Oncology
Drug Development

SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

21st February 2023
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Drug Development

BioMed X Launches New T Cell Immunology Discovery Platform

21st February 2023
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Drug Development

Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

21st February 2023
Biotech Companies In China Look To Have A Global Footprint
Drug Development

Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

21st February 2023
Drug Development

Receptor Location Significant For Psychedelic Drug Effect

21st February 2023
Next Post
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers

DoKaSch Temperature Solutions and ANA sign master rental agreement

Latest News

United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
News

DoKaSch Temperature Solutions and ANA sign master rental agreement

21st February 2023
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
FDA Approvals

WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

21st February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
IPR Data Management

Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance

21st February 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In